JP2020505044A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020505044A5 JP2020505044A5 JP2019540095A JP2019540095A JP2020505044A5 JP 2020505044 A5 JP2020505044 A5 JP 2020505044A5 JP 2019540095 A JP2019540095 A JP 2019540095A JP 2019540095 A JP2019540095 A JP 2019540095A JP 2020505044 A5 JP2020505044 A5 JP 2020505044A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- genetically modified
- protein
- composition
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022173206A JP2022191524A (ja) | 2017-01-26 | 2022-10-28 | Ｂ細胞操作 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762450917P | 2017-01-26 | 2017-01-26 | |
| US62/450,917 | 2017-01-26 | ||
| PCT/US2018/015180 WO2018140573A1 (en) | 2017-01-26 | 2018-01-25 | B-cell engineering |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022173206A Division JP2022191524A (ja) | 2017-01-26 | 2022-10-28 | Ｂ細胞操作 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020505044A JP2020505044A (ja) | 2020-02-20 |
| JP2020505044A5 true JP2020505044A5 (https=) | 2020-12-17 |
Family
ID=62979713
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019540095A Withdrawn JP2020505044A (ja) | 2017-01-26 | 2018-01-25 | Ｂ細胞操作 |
| JP2022173206A Pending JP2022191524A (ja) | 2017-01-26 | 2022-10-28 | Ｂ細胞操作 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022173206A Pending JP2022191524A (ja) | 2017-01-26 | 2022-10-28 | Ｂ細胞操作 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20190352614A1 (https=) |
| EP (1) | EP3573464A4 (https=) |
| JP (2) | JP2020505044A (https=) |
| KR (1) | KR20190111063A (https=) |
| CN (1) | CN110536963A (https=) |
| AU (1) | AU2018212652B2 (https=) |
| BR (1) | BR112019015355A2 (https=) |
| CA (1) | CA3051113A1 (https=) |
| IL (1) | IL268110B2 (https=) |
| MX (1) | MX2019008844A (https=) |
| WO (1) | WO2018140573A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| WO2015105955A1 (en) | 2014-01-08 | 2015-07-16 | Flodesign Sonics, Inc. | Acoustophoresis device with dual acoustophoretic chamber |
| US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
| US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
| US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
| WO2018140573A1 (en) * | 2017-01-26 | 2018-08-02 | Sangamo Therapeutics, Inc. | B-cell engineering |
| US11939594B2 (en) * | 2017-03-16 | 2024-03-26 | Seattle Children's Hospital | Engraftable cell-based immunotherapy for long-term delivery of therapeutic proteins |
| WO2019118921A1 (en) | 2017-12-14 | 2019-06-20 | Flodesign Sonics, Inc. | Acoustic transducer drive and controller |
| JP7578590B2 (ja) | 2018-10-18 | 2024-11-06 | インテリア セラピューティクス，インコーポレーテッド | 第ｉｘ因子を発現するための組成物及び方法 |
| EP4070855B1 (en) | 2019-11-01 | 2025-12-24 | Kyoto Prefectural Public University Corporation | B-cell antibody receptor and use thereof |
| EP4127188A4 (en) | 2020-03-31 | 2024-08-21 | Walking Fish Therapeutics | MODIFIED B CELLS AND METHODS OF USE THEREOF |
| WO2023192936A2 (en) * | 2022-03-30 | 2023-10-05 | Fred Hutchinson Cancer Center | Systems and methods to produce b cells that express selected antibodies and gene products |
| WO2024151683A2 (en) * | 2023-01-09 | 2024-07-18 | Walking Fish Therapeutics, Inc. | HUMAN B CELL ENGINEERED TO EXPRESS IgA AND IgM ANTIBODIES FOR THERAPEUTIC USE |
| WO2024196669A2 (en) * | 2023-03-17 | 2024-09-26 | Walking Fish Therapeutics, Inc. | Methods for in vivo editing of b cells |
| EP4698191A2 (en) * | 2023-04-17 | 2026-02-25 | Be Biopharma, Inc. | Engineered cell preparations for treatment of niemann pick b disease |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003901511A0 (en) * | 2003-03-28 | 2003-04-17 | Bionomics Limited | Nucleic acid molecules associated with angiogenesis II |
| EP1804839B1 (en) * | 2004-09-22 | 2012-03-14 | St. Jude Children's Research Hospital | Improved expression of factor ix in gene therapy vectors |
| AU2010235161B2 (en) * | 2009-04-09 | 2015-01-22 | Sangamo Therapeutics, Inc. | Targeted integration into stem cells |
| CN105683376A (zh) * | 2013-05-15 | 2016-06-15 | 桑格摩生物科学股份有限公司 | 用于治疗遗传病状的方法和组合物 |
| WO2016014837A1 (en) * | 2014-07-25 | 2016-01-28 | Sangamo Biosciences, Inc. | Gene editing for hiv gene therapy |
| HUE055583T2 (hu) * | 2014-09-16 | 2021-12-28 | Sangamo Therapeutics Inc | Eljárások és készítmények nukleáz által közvetített genommódosításhoz és -javításhoz hematopoetikus õssejtekben |
| DK3234107T3 (da) * | 2014-12-19 | 2022-10-17 | Immusoft Corp | B-celler til in vivo-levering af terapeutiske midler |
| AU2016243052C1 (en) * | 2015-04-03 | 2022-11-24 | Dana-Farber Cancer Institute, Inc. | Composition and methods of genome editing of B-cells |
| HRP20240338T1 (hr) * | 2015-06-24 | 2024-05-24 | Janssen Biotech, Inc. | Imunomodulacija i liječenje solidnih tumora s protutijelima koja se specifično vežu na cd38 |
| EP3322297B1 (en) * | 2015-07-13 | 2024-12-04 | Sangamo Therapeutics, Inc. | Delivery methods and compositions for nuclease-mediated genome engineering |
| CA3010738A1 (en) * | 2016-01-15 | 2017-07-20 | Sangamo Therapeutics, Inc. | Methods and compositions for the treatment of neurologic disease |
| WO2018140573A1 (en) * | 2017-01-26 | 2018-08-02 | Sangamo Therapeutics, Inc. | B-cell engineering |
| MY197772A (en) * | 2017-04-10 | 2023-07-13 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against leukemias and other cancers |
| BR112019026622A2 (pt) * | 2017-06-16 | 2020-06-30 | Sangamo Therapeutics, Inc. | disrupção direcionada de receptores de célula t e/ou hla |
| CA3071683A1 (en) * | 2017-08-08 | 2019-02-14 | Sangamo Therapeutics, Inc. | Chimeric antigen receptor mediated cell targeting |
| EP3706766A4 (en) * | 2017-11-09 | 2021-08-18 | Sangamo Therapeutics, Inc. | GENETIC MODIFICATION OF THE CYTOCINE INDUCTIBLE SH2-CONTAINING PROTEIN (CISH) GENE |
| US20230158070A1 (en) * | 2018-01-30 | 2023-05-25 | Cellectis | Combination comprising allogeneic immune cells deficient for an antigen present on both t-cells and pathological cells and therapeutic antibody against said antigen |
| SG11202101773WA (en) * | 2018-08-29 | 2021-03-30 | Nanjing Legend Biotech Co Ltd | Anti-mesothelin chimeric antigen receptor (car) constructs and uses thereof |
| WO2020112860A1 (en) * | 2018-11-30 | 2020-06-04 | Intima Bioscience, Inc. | Methods of identifying immunomodulatory genes |
-
2018
- 2018-01-25 WO PCT/US2018/015180 patent/WO2018140573A1/en not_active Ceased
- 2018-01-25 BR BR112019015355A patent/BR112019015355A2/pt not_active IP Right Cessation
- 2018-01-25 KR KR1020197023790A patent/KR20190111063A/ko not_active Ceased
- 2018-01-25 IL IL268110A patent/IL268110B2/en unknown
- 2018-01-25 JP JP2019540095A patent/JP2020505044A/ja not_active Withdrawn
- 2018-01-25 EP EP18744407.0A patent/EP3573464A4/en not_active Withdrawn
- 2018-01-25 MX MX2019008844A patent/MX2019008844A/es unknown
- 2018-01-25 US US16/480,939 patent/US20190352614A1/en not_active Abandoned
- 2018-01-25 CA CA3051113A patent/CA3051113A1/en active Pending
- 2018-01-25 AU AU2018212652A patent/AU2018212652B2/en not_active Ceased
- 2018-01-25 CN CN201880021264.1A patent/CN110536963A/zh active Pending
-
2022
- 2022-10-28 JP JP2022173206A patent/JP2022191524A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020505044A5 (https=) | ||
| Wienert et al. | Wake-up sleepy gene: reactivating fetal globin for β-hemoglobinopathies | |
| Staal et al. | Autologous stem-cell-based gene therapy for inherited disorders: state of the art and perspectives | |
| JP2017500061A5 (https=) | ||
| Kumar et al. | Clinical development of gene therapy: results and lessons from recent successes | |
| JP2020500162A5 (https=) | ||
| JP2016539627A5 (https=) | ||
| De Ciuceis et al. | Immune mechanisms in hypertension | |
| Amelio et al. | p63 the guardian of human reproduction | |
| Kohn | Gene therapy for blood diseases | |
| JP2017504354A5 (https=) | ||
| US12385070B2 (en) | Homology directed repair compositions for the treatment of hemoglobinopathies | |
| Paladini et al. | The multifaceted nature of aminopeptidases ERAP1, ERAP2, and LNPEP: from evolution to disease | |
| Naeimi Kararoudi et al. | Clustered regularly interspaced short palindromic repeats/Cas9 gene editing technique in xenotransplantation | |
| ES3032739T3 (en) | Genetically engineered hematopoietic stem cell as a platform for systemic protein expression | |
| JP2021513338A5 (https=) | ||
| Ly et al. | Gene therapy in the treatment of heart failure | |
| EP3765617A1 (en) | Systems and methods for the treatment of hemoglobinopathies | |
| Kyriakopoulou et al. | Gene editing innovations and their applications in cardiomyopathy research | |
| Bottino et al. | Use of genetically-engineered pig donors in islet transplantation | |
| Naldini et al. | The EHA research roadmap: hematopoietic stem cell gene therapy | |
| Barbarani et al. | β-Hemoglobinopathies: the test bench for genome editing-based therapeutic strategies | |
| Wu et al. | Multiple gene modifications of pigs for overcoming obstacles of xenotransplantation | |
| Maeder et al. | 687. Therapeutic correction of an LCA-causing splice defect in the CEP290 gene by CRISPR/Cas-mediated genome editing | |
| Guo et al. | Hemophilia gene therapy: New development from bench to bed side |